drugset / Trial / NCT04161014

The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial

NCT04161014

NaSingle-groupOpen-labelSupportive care

Summary

Prospective clinical pilot study for subjects diagnosed with Occupational Progressive Pneumoconiosis. Subjects will be treated with Nintedanib 150mg twice daily for 3 years.

Timeline

Start
2020-10-09
Primary completion
2024-12
Completion
2025-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Nintedanib Small molecule 150 mg